Loading clinical trials...
Loading clinical trials...
An Open-Label, Two-Part, Two-Period Crossover Study to Determine Bioequivalence Between Nemtabrutinib FFP and FMF2 Formulations & FMF1 and FMF2 Formulations at 65 mg Single Dose in Healthy Male Participants
Conditions
Interventions
Nemtabrutinib
Locations
1
United States
QPS-MRA, LLC-Early Phase (Site 0002)
South Miami, Florida, United States
Start Date
August 28, 2023
Primary Completion Date
November 13, 2023
Completion Date
November 13, 2023
Last Updated
September 19, 2024
NCT05537896
NCT04841447
NCT03159702
NCT07145359
NCT05391022
NCT04347226
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions